GleamWall
中文EN

ARTV Artiva Biotherapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1817241 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-23.9%
TTM EPS YoY-129.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-43.6%
ROA-39.9%
ROIC (approx.)-45.8%
Asset turnover—

Leverage & solvency

Liabilities / assets6.5%
Debt / equity0.00x
Current ratio19.88x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-5.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$251,000
R&D expense$69.54M$50.33M
SG&A expense$20.27M$17.20M
Operating income-$89.81M-$67.28M
Pretax income$83.90M$65.40M
Income tax$0$0
Net income-$83.86M-$65.37M
EBITDA-$87.21M-$64.85M
EPS (basic)-3.43-5.81
EPS (diluted)-3.43-5.81
Weighted avg. shares (diluted)24.44M11.26M
Balance sheet
Cash & equivalents$26.70M$40.49M
Short-term investments$81.31M$145.19M
Receivables—$0
Current assets$112.67M$188.63M
PP&E, net$6.62M$6.37M
Total assets$130.94M$209.58M
Current liabilities$13.09M$12.25M
Total liabilities$20.97M$22.94M
Shareholders' equity$109.97M$186.64M
Cash flow statement
Operating cash flow-$76.75M-$55.03M
Capital expenditure$2.59M$642,000
Free cash flow-$79.34M-$55.67M
Investing cash flow$63.41M-$120.46M
Financing cash flow$9,000$162.23M
Depreciation & amortization$2.60M$2.43M
Stock-based compensation$6.82M$6.98M

Free plan shows the latest 2 periods; Pro shows all 3 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.